- Home
- SDA vs GALT Comparison
SDA vs GALT Comparison
Compare SDA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDA | GALT |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | China | United States |
| Employees | 560 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.5M | 199.2M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | SDA | GALT |
|---|---|---|
| Price | $1.78 | $2.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.75 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 455.0K | 340.2K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $15.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $1.15 |
| 52 Week High | $4.55 | $7.13 |
Technical Indicators
Market Signals| Indicator | SDA | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 45.95 |
| Support Level | $1.54 | $2.88 |
| Resistance Level | $2.18 | $3.32 |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 15.62 | 32.15 |
Price Performance
Historical ComparisonAbout SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.